Real-world treatment outcomes of immune checkpoint inhibitors used off-label in oncology: A comprehensive cancer institution experience.
cancer
immune checkpoint inhibitors
off-label use
survival
treatment outcomes
Journal
Pharmacology research & perspectives
ISSN: 2052-1707
Titre abrégé: Pharmacol Res Perspect
Pays: United States
ID NLM: 101626369
Informations de publication
Date de publication:
Feb 2024
Feb 2024
Historique:
revised:
26
10
2023
received:
24
07
2023
accepted:
11
12
2023
medline:
9
1
2024
pubmed:
9
1
2024
entrez:
9
1
2024
Statut:
ppublish
Résumé
Off-label use (OLU) is quite common in oncology due to the complexity of cancer and the time-consuming regulatory process. However, outcomes of OLU in cancer treatment remain unclear. This study aimed to evaluate the overall survival (OS), event-free survival (EFS), duration of treatment (DOT), and reason for treatment discontinuation in patients receiving immune checkpoint inhibitors (ICI) as OLU for solid tumors from 2011 to 2020. The study collected data on 356 episodes (353 patients), with a median age of 64.4 years, 36.2% women, and 14.6% ECOG ≥ 2. Median OS was 15.7 (11.9-18.7) months, and median EFS was 5.4 (3.8-6.6) months. Men, patients with metastatic disease or ECOG-PS higher than 1, had worse survival outcomes. The findings derived from this study provide valuable information regarding the real-world use of ICI-OLU and contributes to enhancing the decision-making process for individuals with cancer. Further research on immunotherapy outcomes of OLU in cancer is needed.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1167Informations de copyright
© 2024 The Authors. Pharmacology Research & Perspectives published by British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics and John Wiley & Sons Ltd.
Références
Weda M, Hoebert J, Moltó Puigmarti C, et al. Study on off-label use of medicinal products in the European Union. Eur Union. 2017;1-185. https://op.europa.eu/en/publication-detail/-/publication/ecf85518-d376-11e9-b4bf-01aa75ed71a1/language-e
Drogovoz SM, Starikov VI, Ivantsyk LB, Shchokina KG. Experience and prospects for the use of off-label drugs in oncology. Exp Oncol [Internet]. 2021;43(1):1-5. https://pubmed.ncbi.nlm.nih.gov/33785726/
Saiyed MM, Ong PS, Chew L. Off-label drug use in oncology: a systematic review of literature. J Clin Pharm Ther. 2017;42(3):251-258.
Levêque D. Off-label use of targeted therapies in oncology. World J Clin Oncol [Internet]. 2016;7(2):253-257. http://www.ncbi.nlm.nih.gov/pubmed/27081648
From laboratory to patient: the journey of a medicine assessed by EMA [Internet]. [cited 2021 Feb 10]. https://www.ema.europa.eu/en/documents/other/laboratory-patient-journey-centrally-authorised-medicine_en.pdf
Medina AA, Artiles-medina A, Sáchez-cuervo M, et al. Medicines in exceptional circumstances for solid tumours: focusing on evidence, effectiveness, and toxicity profiles. Farm Hosp. 2022;46(3):133-145.
Danés I, Agustí A, Vallano A, et al. Outcomes of off-label drug uses in hospitals: a multicentric prospective study. Eur J Clin Pharmacol. 2014;70(11):1385-1393.
Ibáñez C, Fontanals S, Mesia R, Clopés A. Comments on “off-label despite high-level evidence: a clinical practice review of commonly used off-patent cancer medicines.” ESMO Open [Internet]. 2023 [cited 2023 May 16];8(3):101212. https://linkinghub.elsevier.com/retrieve/pii/S2059702923004386
Fontanals S, Esteve A, González A, et al. Real-world treatment outcomes of medicines used in special situations (off-label and compassionate use) in oncology and hematology: a retrospective study from a comprehensive cancer institution. Cancer Med [Internet]. 2023 [cited 2023 Sep 21];12(16):17112-17125. 10.1002/cam4.6360
Zarkavelis G, Amylidi AL, Verbaanderd C, et al. Off-label despite high-level evidence: a clinical practice review of commonly used off-patent cancer medicines. ESMO Open [Internet]. 2023 [cited 2023 Jun 17];8(1):100604. /pmc/articles/PMC10024100/
Dall'Olio FG, Maggio I, Massucci M, Mollica V, Fragomeno B, Ardizzoni A. ECOG performance status ≥2 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors-a systematic review and meta-analysis of real world data. Lung Cancer [Internet]. 2020 [cited 2023 May 16];145:95-104. https://pubmed.ncbi.nlm.nih.gov/32417680/
Irelli A, Sirufo MM, D'Ugo C, Ginaldi L, De Martinis M. Sex and gender influences on cancer immunotherapy response. Biomedicine. 2020;8(7):1-23.